NCT05282953View on ClinicalTrials.gov

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

August 10, 2023

Study Completion Date

July 31, 2026

Conditions
Retinitis PigmentosaChoroideremia
Interventions
DRUG

KIO-301

KIO-301 intravitreal injection at ascending doses

Trial Locations (2)

5000

RECRUITING

Royal Adeliade Hospital, Adelaide

5006

RECRUITING

Harley Eye Clinic, North Adelaide

Sponsors
All Listed Sponsors
lead

Kiora Pharmaceuticals, Inc.

INDUSTRY

NCT05282953 - A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | Biotech Hunter | Biotech Hunter